Altimmune（NASDAQ:ALT）报告2024年第四季度每股亏损为$(0.33)，符合分析师的共识预期。相比去年同期每股亏损$(0.54)，亏损减少了38.89%。公司本季度报告收入为$5.00千，与去年同期的$37.00千相比下降了86.49%。
以上内容来自Benzinga Earnings专栏，原文如下：
Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.33) per share which met the analyst consensus estimate. This is a 38.89 percent increase over losses of $(0.54) per share from the same period last year. The company reported $5.00 thousand in sales this quarter. This is a 86.49 percent decrease over sales of $37.00 thousand the same period last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.